The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
ApexOnco Front Page
Recent articles
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
But the new focus on a predictive biomarker could cut the market in half.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
On a wing and a prayer Leap heads for phase 3.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
